ROSIGLITAZONE VS TELMISARTAN ON THE MODIFICATION OF INSULIN-RESISTANCE CKD

罗格列酮与替米沙坦对胰岛素抵抗 CKD 的改变

• 批准号: 7717920
• 负责人: BRYAN David MYERS
• 金额: $ 0.1万
• 依托单位: STANFORD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-12-01 至 2008-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7717920
• 关键词: 2,4-thiazolidinedione; Address; Angiotensin II Receptor; Attenuated; Chronic Kidney Failure; Computer Retrieval of Information on Scientific Projects Database; Development; Disease Outcome; Dyslipidemias; Funding; Grant; Guidelines; Hypertension; Inflammation; Institution; Insulin Resistance; Intervention; Kidney Diseases; Modification; Morbidity - disease rate; Patients; Pilot Projects; Prevalence; Property; Rate; Research; Research Personnel; Resources; Risk Factors; Source; Thiazolidinediones; United States National Institutes of Health; base; cardiovascular risk factor; mortality; novel; outcome forecast; rosiglitazone; telmisartan

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The prevalence of chronic kidney disease (CKD) is growing at an alarming rate and discovering when common complications develop including insulin resistance is critical to our ability to anticipate morbidity and mortality and treat patients more effectively. Insulin resistance has been associated with the development of cardiovascular risk factors including hypertension, dyslipidemia, inflammation and perhaps accelerated progression of CKD. Such risk factors in the setting of early renal disease merit a pilot study of a potential intervention to reverse insulin resistance. There are no specific guidelines included in Kidney Disease Outcome Quality Initiative (K-DOQI) that address treatment of insulin resistance due to CKD. The demonstration that thiazolidinedione (TZD) therapy or that telmisartan, an angiotensin II receptor blocker with novel properties, reverses insulin resistance in CKD could provide a basis for long-term therapy that attenuates the complications and prognosis of CKD.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 慢性肾脏病（CKD）的患病率正以惊人的速度增长，发现常见并发症（包括胰岛素抵抗）何时发生对我们预测发病率和死亡率以及更有效地治疗患者的能力至关重要。 胰岛素抵抗与心血管危险因素的发展相关，包括高血压、血脂异常、炎症以及可能加速的CKD进展。 在早期肾脏疾病的背景下，这些危险因素值得进行一项潜在干预措施的初步研究，以逆转胰岛素抵抗。 肾脏疾病结局质量倡议（K-DOQI）中没有针对CKD所致胰岛素抵抗治疗的具体指南。 噻唑烷二酮（TZD）治疗或替米沙坦（一种具有新特性的血管紧张素II受体阻滞剂）逆转CKD胰岛素抵抗的证据可为减轻CKD并发症和预后的长期治疗提供基础。